BOEHRINGER-INGELHEIM
13.5.2020 14:02:08 CEST | Business Wire | Press release
Boehringer Ingelheim and CDR-Life today announced they have entered into a collaboration and licensing agreement to research and develop antibody fragment-based therapeutics for geographic atrophy (GA). GA is a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration (AMD) for which there is no current treatment. Together, with Boehringer Ingelheim’s expertise in the therapeutic development of biologics and CDR-Life’s strong know-how in antibody engineering, the two companies will progress CDR-Life’s preclinical candidate, with the aim to preserve sight for patients with GA.
“Partnering with CDR-Life provides Boehringer Ingelheim with the opportunity to collaborate with a team that has a proven track record developing antibody fragment-based therapeutics for retinal diseases,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “The prospect of losing one’s sight is frightening. We are committed to transformational therapies that have the potential to succeed in preserving the health and vision of patients with retinal diseases, such as geographic atrophy.”
Utilizing antibody fragment-based technology, which retains the specificity of an antibody while significantly reducing the size of the molecule, may have significant advantages over traditional large molecule approaches for the treatment of retinal diseases, such as GA. When applied to the eye via intravitreal injection, high affinity antibody fragment therapies have the potential to reach the retinal pigment epithelial cells where degeneration is known to occur. This precise technology may help decrease the cellular stresses caused by AMD and prevent further loss of sight.
“Boehringer Ingelheim is one of the leading research and development companies in the field of biologics,” said Christian Leisner, Ph.D., Chief Executive Officer at CDR-Life. “This is an exciting partnership that brings together Boehringer Ingelheim’s development expertise and CDR-Life’s innovative antibody fragments to provide hope for people living with a blinding retinal disease. We look forward to advancing this project towards the clinic together with the Boehringer Ingelheim team.”
Boehringer Ingelheim takes a holistic approach to the development of novel retinal disease therapies, targeting key mechanisms in the pathogenesis of retinal diseases. By leveraging existing expertise in oncology, inflammation, neurodegeneration, fibrosis and cardiometabolic diseases, the company has built a comprehensive portfolio of next generation retinal therapy approaches in various stages of development up to Phase 2 in macular degeneration and diabetic retinal diseases.
CDR-Life´s preclinical program utilizing antibody fragment-based technology complements this growing portfolio, providing an innovative approach to treat GA.
Under the terms of the agreement, Boehringer Ingelheim will receive an exclusive, worldwide license to develop certain compounds based on CDR-Life´s technology against a specific target and will be responsible for global development and commercialization. CDR-Life will be eligible to receive up to CHF 474.5 million in upfront and success-based milestone payments, as well as research funding and royalties on sales.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/geographicatrophycollabortationwithcdr-life
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005341/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ENGIE and NHOA Energy Break Ground on 320MWh Drogenbos Battery Project in Belgium27.5.2026 13:22:00 CEST | Press release
Construction officially underway, marking a key milestone in the delivery of one of the largest battery storage systems in Benelux NHOA Energy, global provider of utility-scale energy storage systems, joined ENGIE today in marking a significant milestone with the groundbreaking ceremony of a 320MWh Battery Energy Storage System (BESS) at ENGIE’s Drogenbos power station, near Brussels. The ceremony, held this morning in the presence of Hans Bonte, Minister of Energy of the Government of Flanders, Vincent Verbeke, CEO of ENGIE Belgium, Nicolas van den Abeele, Managing Director Renewables & Batteries Benelux of ENGIE, and Giuseppe Artizzu, CEO of NHOA Energy, marked the official start of construction of ENGIE’s third large-scale battery project in Belgium. Awarded under Belgium’s fifth Capacity Remuneration Mechanism (CRM) auction, the project will contribute to the adequacy of the national electricity system under a 15-year contract starting in November 2027. ENGIE has entrusted NHOA Ene
NIQ Launches Survey Groups to Connect Consumer Sentiment with Real Purchase Behavior27.5.2026 13:00:00 CEST | Press release
New integrated capability connects consumer sentiment with real-world purchase data, enabling more confident, action‑driven decisions NIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of Survey Groups in NIQ Discover, a new capability that enables brands and retailers to understand not just what is changing in the market, but why. Available immediately within NIQ Discover, Survey Groups build on NIQ Panel Surveys by linking attitudinal insights to real-world purchase behavior from NIQ’s consumer panels—helping clients uncover the motivations behind performance shifts, identify opportunity gaps, and act with greater confidence in an increasingly complex consumer landscape. What’s New: Survey Groups in Discover Survey Groups make NIQ Panel Survey insights easier to access, analyze, and activate within existing workflows. By grouping survey responses with purchase behavior, clients can: Analyze key consumer segments with greater precision Understand the
Platoon Aviation’s Fleet Will Expand Charter Operations to Become Europe’s Largest Cessna Citation Longitude Fleet27.5.2026 12:00:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced it has entered into a multi-aircraft fleet purchase agreement with Platoon Aviation that positions the Hamburg-based charter operator to become the largest Cessna Citation Longitude fleet owner in Europe. Platoon Aviation provides on-demand private jet travel, serving business and leisure travelers seeking long-range capability, cabin comfort and operational reliability. Deliveries of the Citation Longitude aircraft are expected to begin in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527805306/en/ Platoon Aviation’s fleet will expand charter operations to become Europe’s largest Cessna Citation Longitude fleet. (Photo credit: Textron Aviation) “From performance and cabin experience to the strength of our global support network, the Citation Longitude provides charter operators with the confidence to grow their fleets and serve customers at
ZCG-Backed VENU+ Expands Global Footprint Through Strategic Partnership with Merlin Entertainments27.5.2026 12:00:00 CEST | Press release
Partnership brings next-generation photo capture experiences to leading attractions across Europe, North America, and Asia VENU+, a leading global provider of tech-enabled guest mobility, storage, and entertainment solutions and a portfolio company of Z Capital Group (“ZCG”), today announced a strategic partnership with Merlin Entertainments, a global leader in branded entertainment destinations, to enhance and expand photo capture experiences across Merlin’s international portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527425123/en/ The partnership includes the rollout of VENU+’s Photo Capture platform across 13 Merlin attractions, including flagship destinations such as LEGOLAND® Resorts and the London Eye, spanning Europe, North America, and Asia. The staged implementation is already underway, with several locations operational and additional sites scheduled for activation throughout 2026. The agreement repre
euNetworks launches new quantum-safe private connectivity service powered by Adtran’s encrypted optical transport technology27.5.2026 10:00:00 CEST | Press release
News summary: Developed by euNetworks to deliver the highest levels of protection for sensitive data moving between European data centers Built on Adtran’s solution, euNetworks’ new Quantum Shield service enables quantum-safe encryption across private high-capacity connectivity, with continuous optical and fiber plant monitoring The new offering supports regulated industries with strong assurance against current and emerging cybersecurity threats Adtran and euNetworks today announced their collaboration on the launch of a new quantum-safe private connectivity service, Quantum Shield. euNetworks has developed Quantum Shield using Adtran’s optical transport technology to augment its broader architecture, which is designed to deliver secure, scalable data center connectivity across euNetworks’ pan-European network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526610601/en/ Adtran’s encrypted optical transport technology is
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom